|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||145.4 kg/mol g·mol−1|
|(what is this?)|
Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor as a treatment for pain. Tanezumab was discovered and developed by Rinat Neuroscience and was acquired by Pfizer in 2006.
A Phase III trial published in 2013 found tanezumab was superior to placebo for painful hip osteoarthritis.
At February 19, 2019 the co-development partners - Eli Lilly and Pfizer - announced that treatment with tanezumab 10 mg met the primary endpoint, demonstrating a statistically significant improvement in pain at 16 weeks compared to placebo (however, 5 mg arm demonstrated a numerical improvement in pain, but did not reach statistical significance compared to placebo at the week 16 analysis). 
- "Anti-ngf antibodies and methods using same". 2005.
- "Tanezumab in Osteoarthritis of the Knee". 2009
- "Tanezumab in Osteoarthritis Of The Hip".
- "Phase II trials involving Tanezumab".
- "Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial". Arthritis Rheum. 65: 1795–803. Jul 2013. doi:10.1002/art.37950. PMID 23553790.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This analgesic-related article is a stub. You can help Wikipedia by expanding it.|